Literature DB >> 3921572

Studies on the procurement of blood coagulation factor VIII: effects of plasma freezing rate and storage conditions on cryoprecipitate quality.

A Farrugia, C Prowse.   

Abstract

Plasma was frozen and stored in different ways before processing to cryoprecipitate by a standard thawing technique. Freezing rate was found to be important with slow freezing having a deleterious effect on cryoprecipitate quality. Storage of frozen plasma at constant temperatures for periods up to six months had no effect on the quality of cryoprecipitate, with no difference being found for plasma stored at -20 degrees C or -40 degrees C. Subjecting frozen plasma to deliberate temperature fluctuations resulted in a considerable increase in the amount of fibrinogen recovered in cryoprecipitate, with the factor VIII yield being relatively unaffected.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3921572      PMCID: PMC499172          DOI: 10.1136/jcp.38.4.433

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  19 in total

1.  Preparation of cryoprecipitated factor VIII concentrates.

Authors:  S J Slichter; R B Counts; R Henderson; L A Harker
Journal:  Transfusion       Date:  1976 Nov-Dec       Impact factor: 3.157

2.  Evaluation of the 'Mason' (continuous-thaw-siphon) method for cryoprecipitate production.

Authors:  C V Prowse; A McGill
Journal:  Vox Sang       Date:  1979       Impact factor: 2.144

3.  The effects of temperature variations on cryoprecipitate.

Authors:  G A Rock; P Tittley
Journal:  Transfusion       Date:  1979 Jan-Feb       Impact factor: 3.157

4.  The potent antihemophilic globulin concentrate derived from a cold insoluble fraction of human plasma: characterization and further data on preparation and clinical trial.

Authors:  E J Hershgold; J G Pool; A R Pappenhagen
Journal:  J Lab Clin Med       Date:  1966-01

5.  Production of high-potency concentrates of antihemophilic globulin in a closed-bag system.

Authors:  J G Pool; A E Shannon
Journal:  N Engl J Med       Date:  1965-12-30       Impact factor: 91.245

6.  Methods for the production of clinically effective intermediate- and high-purity factor-VIII concentrates.

Authors:  J Newman; A J Johnson; M H Karpatkin; S Puszkin
Journal:  Br J Haematol       Date:  1971-07       Impact factor: 6.998

7.  Thaw-siphon technique for production of cryoprecipitate concentrate of factor VIII.

Authors:  E C Mason
Journal:  Lancet       Date:  1978-07-01       Impact factor: 79.321

8.  Antihaemophilic globulin: preparation by an improved cryoprecipitation method and clinical use.

Authors:  D L Brown; R M Hardisty; M H Kosoy; C Bracken
Journal:  Br Med J       Date:  1967-04-08

9.  Contribution to the optimal use of human blood. VII. Increase of the yield of factor VIII in four-donor cryoprecipitate by an improved processing of blood and plasma.

Authors:  C Vermeer; B A Soute; G Ates; H G Brummelhuis
Journal:  Vox Sang       Date:  1976       Impact factor: 2.144

10.  Heterogeneity of human factor VIII. I. Characterization of factor VIII present in the supernatant of cryoprecipitate.

Authors:  J Over; B N Bouma; J A van Mourik; J J Sixma; R Vlooswijk; I Bakker-Woudenberg
Journal:  J Lab Clin Med       Date:  1978-01
View more
  1 in total

1.  Biochemical and cellular markers differentiate recovered, in-line filtered plasma, and plasma obtained by apheresis methods.

Authors:  Jürgen Siekmann; Alfred Weber; Christoph Bauer; Peter L Turecek
Journal:  Vox Sang       Date:  2021-06-10       Impact factor: 2.996

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.